Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02491788 · ClinicalTrials.gov registry record · Phase 4
Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers
A Phase 4 study, sponsored by VA Palo Alto Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT02491788: Completed Phase 4 study, sponsored by VA Palo Alto Health Care System.
NCT02491788 is a Phase 4 study that has completed, run by VA Palo Alto Health Care System. The registered enrollment target is 19 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02491788, a Phase 4 study, has completed, sponsored by VA Palo Alto Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
Primary Outcome
Change in average of the total amount of sleep occurring during daytime sleep episodes following night shift work, as compared to baseline
Interventions
- DRUG Placebo
- DRUG Suvorexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2019-08-01 |
| Phase | Phase 4 |
What the finished NCT02491788 record still lists
NCT02491788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02491788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02491788 about?
NCT02491788 is a clinical study titled "Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers". The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and su...
What is the current status of trial NCT02491788?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2016-02-01. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT02491788?
The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT02491788?
This trial is sponsored by VA Palo Alto Health Care System, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02491788's enrollment target sits among peer trials
19 1834th of 2000 higher than 159 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI